Meet the six startups that will be working with Shell and Greentown Labs for the next six months. Photo via Greentown

Greentown Labs has named the six participating climatetech startups for an accelerator for a global energy leader.

Shell and Greentown Labs announced the cohort for Greentown Go Make 2023 — a program designed to accelerate partnerships between startups and corporates to advance carbon utilization, storage, and traceability solutions with manufacturing in mind. Shell, which invests in net-zero and carbon-removal technologies, is hoping to strategically align with startups within carbon utilization, storage, and traceability across the energy transition spectrum.

“At Greentown Labs we recognize and appreciate the role energy incumbents must play in the energy transition, and we’re eager to facilitate meaningful partnerships between these impressive startups and Shell—not only to advance these technologies but also to help Shell achieve its sustainability goals,” Kevin Knobloch, CEO and President of Greentown Labs, says in a news release. “We know carbon utilization, storage, and traceability will play a critical role in our collective efforts to reach net-zero, and we’re enthusiastic about the potential impact these companies can have in that work.”

The cohort, selected from 110 applications, is co-located at Greentown's Houston and Somerville, Massachusetts, locations and includes:

  • Portland-based Caravel Bio is developing a novel synthetic biology platform that uses microbial spores and enzymes to create catalysts that are long-lasting and can withstand extreme conditions and environments.
  • Circularise, which is based in the Netherlands, is developing a blockchain platform that provides digital product passports for end-to-end traceability and secure data exchange for industrial supply chains.
  • Corumat, based in Washington, converts organic waste into high-performance, insulating, greaseproof, and biodegradable packaging materials.
  • Cambridge, Massachusetts-headquartered Lydian develops a fully electrified reactor that can convert a variety of gaseous, non-fossil feedstocks into pure syngas with high efficiency.
  • Maple Materials from Richmond, California is developing a low-cost electrolysis process to split carbon dioxide into graphite and oxygen.
  • Ontario, Canada-founded Universal Matter develops a proprietary Flash Joule Heating process that converts carbon waste into high-value and high-performance graphene materials to efficiently create sustainable circular economies.

The program, which includes $15,000 in non-dilutive stipend funding for each company, will work closely with Shell and Greentown over six months via mentorship, networking opportunities, educational workshops, and partnership-focused programming to support collaboration. Go Make 2023 concludes with a showcase event on March 27 at Greentown Labs’ Houston location.

This week, Shell announced another accelerator cohort it's participating in. The Shell GameChanger Accelerator, a partnership with the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL), named four West Coast climatetech companies: DTE Materials, Hexas Biomass, Invizyne Technologies, and ZILA BioWorks. The program provides early-stage cleantech startups with access to experts and facilities to reduce technology development risk and accelerate commercialization of new cleaner technologies.

“Tackling the climate challenge requires multifaceted solutions. At Shell, we believe technology that removes carbon dioxide from the atmosphere will be essential for lowering emissions from energy and chemical products,” Yesim Jonsson, Shell’s GCxN program manager, says in a statement. “The companies in GCxN's sixth cohort embody these objectives and have the potential to usher in a more sustainable future.”

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”